USD 283.99
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CI | 1.1 | 2.5 | 6.9 | -19.6 | -17.6 | -7.9 | 18.3 | 33.6 | 161.8 | 4788.0 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CI |
| name | Cigna Corporation |
| price | 283.99 |
| changes percentage | 1.0748 |
| change | 3.02 |
| day low | 279.47 |
| day high | 286.39 |
| year high | 370.83 |
| year low | 262.03 |
| market cap | 78992670470 |
| price avg 50 | 303.9792 |
| price avg 200 | 332.9985 |
| exchange | NYSE |
| volume | 1532015 |
| avg volume | 2095088 |
| open | 281.09 |
| previous close | 280.97 |
| eps | 10.56 |
| pe | 26.89 |
| earnings announcement | 2025-01-30T13:30:00.000+0000 |
| shares outstanding | 278153000 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001739940 | |||
| revenue | 195187000000 | 180031000000 | 8.42 |
| gross profit | 0 | 0 | NaN |
| gross profit ratio | 0.81 | 0.82 | -0.88 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 186651000000 | 171581000000 | 8.78 |
| interest income | 0 | 0 | NaN |
| interest expense | 1446000000 | 1228000000 | 17.75 |
| ebitda | 9574000000 | 12908000000 | -25.83 |
| ebitdaratio | 0.05 | 0.07 | -25.70 |
| operating income | 8536000000 | 8450000000 | 1.02 |
| operating income ratio | 0.04 | 0.05 | -16.87 |
| net income | 5164000000 | 6704000000 | -22.97 |
| net income ratio | 0.03 | 0.04 | -28.71 |
| eps | 17.57 | 21.66 | -18.88 |
Revenue Growth: revenue increased to 195,187 million in 2023 from 180,031 million in 2022 representing a change of 8.42%. This indicates a sales growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 9,574 million in 2023 from 12,908 million in 2022 representing a change of -25.83%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 8,536 million in 2023 from 8,450 million in 2022 representing a change of 1.02%. The increase in operating income indicates better operational performance and increased profitability.
Operating Expenses: Operating Expenses increased to 186,651 million in 2023 from 171,581 million in 2022 representing a change of 8.78%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to 5,164 million in 2023 from 6,704 million in 2022 representing a change of -22.97%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 17.57 in 2023 from 17.57 in 2022 representing a change of -18.88%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001739940 | |||
| revenue | 63694000000 | 60475000000 | 5.32 |
| gross profit | 54167000000 | 0 | NaN |
| gross profit ratio | 0.85 | 0.84 | 0.92 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 51514000000 | 58063000000 | -11.28 |
| interest income | 0 | 0 | NaN |
| interest expense | 376000000 | 375000000 | 0.27 |
| ebitda | 2218000000 | 3087000000 | -28.15 |
| ebitdaratio | 0.03 | 0.04 | -12.69 |
| operating income | 1732000000 | 2412000000 | -28.19 |
| operating income ratio | 0.03 | 0.04 | -31.82 |
| net income | 739000000 | 1548000000 | -52.26 |
| net income ratio | 0.01 | 0.03 | -54.67 |
| eps | 2.65 | 5.51 | -51.91 |
Revenue Growth: revenue increased to 63,694 million in 2024Q3 from 60,475 million in 2024Q2 representing a change of 5.32%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 54,167 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 51,514 million in 2024Q3 from 58,063 million in 2024Q2 representing a change of -11.28%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Net Income: Net income increased to 739 million in 2024Q3 from 1,548 million in 2024Q2 representing a change of -52.26%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 2,218 million in 2024Q3 from 3,087 million in 2024Q2 representing a change of -28.15%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 1,732 million in 2024Q3 from 2,412 million in 2024Q2 representing a change of -28.19%. The decrease in operating income indicates worse operational performance and decreased profitability.
Earnings per Share (EPS): EPS increased to 2.65 in 2024Q3 from 2.65 in 2024Q2 representing a change of -51.91%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001739940 | |||
| total assets | 152761000000 | 143932000000 | 6.13 |
| total liabilities | 106410000000 | 98981000000 | 7.51 |
| total equity | 46351000000 | 44951000000 | 3.11 |
| cash and cash equivalents | 7822000000 | 5924000000 | 32.04 |
| short term investments | 925000000 | 905000000 | 2.21 |
| long term investments | 17985000000 | 905000000 | 1887.29 |
| total current assets | 37351000000 | 28790000000 | 29.74 |
| total non current assets | 110575000000 | 82982000000 | 33.25 |
| total current liabilities | 48716000000 | 10768000000 | 352.41 |
| total non current liabilities | 57694000000 | 10768000000 | 435.79 |
| common stock | 4000000 | 4000000 | 0.00 |
| retained earnings | 41652000000 | 37874000000 | 9.98 |
| total debt | 30930000000 | 31093000000 | -0.52 |
Total Assets: Total Assets increased to 152,761 million in 2023 from 143,932 million in 2022 representing a change of 6.13%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 46,351 million in 2023 from 44,951 million in 2022 representing a change of 3.11%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 7,822 million in 2023 from 5,924 million in 2022 representing a change of 32.04%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 925 million in 2023 from 905 million in 2022 representing a change of 2.21%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 37,351 million in 2023 from 28,790 million in 2022 representing a change of 29.74%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 41,652 million in 2023 from 37,874 million in 2022 representing a change of 9.98%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 30,930 million in 2023 from 31,093 million in 2022 representing a change of -0.52%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 106,410 million in 2023 from 98,981 million in 2022 representing a change of 7.51%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 48,716 million in 2023 from 10,768 million in 2022 representing a change of 352.41%. This indicates a higher short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001739940 | |||
| total assets | 157639000000 | 150851000000 | 4.50 |
| total liabilities | 115341000000 | 109324000000 | 5.50 |
| total equity | 42298000000 | 41527000000 | 1.86 |
| cash and cash equivalents | 5888000000 | 6788000000 | -13.26 |
| short term investments | 864000000 | 1068000000 | -19.10 |
| long term investments | 15270000000 | 1068000000 | 1329.78 |
| total current assets | 49222000000 | 46215000000 | 6.51 |
| total non current assets | 108417000000 | 104636000000 | 3.61 |
| total current liabilities | 57060000000 | 55373000000 | 3.05 |
| total non current liabilities | 58281000000 | 53951000000 | 8.03 |
| common stock | 4000000 | 4000000 | 0.00 |
| retained earnings | 42480000000 | 42132000000 | 0.83 |
| total debt | 32802000000 | 31892000000 | 2.85 |
Total Assets: Total Assets increased to 157,639 million in 2024Q3 from 150,851 million in 2024Q2 representing a change of 4.5%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 42,298 million in 2024Q3 from 41,527 million in 2024Q2 representing a change of 1.86%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 49,222 million in 2024Q3 from 46,215 million in 2024Q2 representing a change of 6.51%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 42,480 million in 2024Q3 from 42,132 million in 2024Q2 representing a change of 0.83%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 115,341 million in 2024Q3 from 109,324 million in 2024Q2 representing a change of 5.5%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 5,888 million in 2024Q3 from 6,788 million in 2024Q2 representing a change of -13.26%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 864 million in 2024Q3 from 1,068 million in 2024Q2 representing a change of -19.1%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 57,060 million in 2024Q3 from 55,373 million in 2024Q2 representing a change of 3.05%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 32,802 million in 2024Q3 from 31,892 million in 2024Q2 representing a change of 2.85%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001739940 | |||
| net change in cash | 2361000000 | 428000000 | 451.64 |
| operating cash flow | 11813000000 | 8656000000 | 36.47 |
| free cash flow | 10240000000 | 7361000000 | 39.11 |
| capital expenditure | -1573000000 | -1295000000 | -21.47 |
| depreciation and amortization | 3035000000 | 2937000000 | 3.34 |
| deferred income tax | -1659000000 | -480000000 | -245.62 |
| stock based compensation | 286000000 | 264000000 | 8.33 |
| accounts payables | 5511000000 | 3334000000 | 65.30 |
| inventory | -868000000 | -1055000000 | 17.73 |
| acquisitions net | -434000000 | 4835000000 | -108.98 |
| investments in property plant and equipment | -1573000000 | -1295000000 | -21.47 |
| net cash used for investing activites | -5174000000 | 3098000000 | -267.01 |
| debt repayment | -278000000 | -500000000 | 44.40 |
| common stock issued | 187000000 | 389000000 | -51.93 |
| common stock repurchased | -2284000000 | -7607000000 | 69.98 |
| dividends paid | -1450000000 | -1384000000 | -4.77 |
| net cash used provided by financing activities | -4294000000 | -11240000000 | 61.80 |
| cash at end of period | 8337000000 | 5976000000 | 39.51 |
| accounts receivables | -2202000000 | -2275000000 | 3.21 |
| cash at beginning of period | 5976000000 | 5548000000 | 7.71 |
Net Change in Cash: Net Change in Cash increased to 2,361 million in 2023 from 428 million in 2022 representing a change of 451.64%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 11,813 million in 2023 from 8,656 million in 2022 representing a change of 36.47%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 10,240 million in 2023 from 7,361 million in 2022 representing a change of 39.11%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -1,573 million in 2023 from -1,295 million in 2022 representing a change of -21.47%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation increased to 286 million in 2023 from 264 million in 2022 representing a change of 8.33%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 5,511 million in 2023 from 3,334 million in 2022 representing a change of 65.3%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to -2,202 in 2023 from -2,275 million in 2022 representing a change of 3.21%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -1,450 million in 2023 from -1,384 million in 2022 representing a change of -4.77%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001739940 | |||
| operating cash flow | 46000000 | 265000000 | -82.64 |
| free cash flow | -353000000 | -105000000 | -236.19 |
| capital expenditure | -399000000 | -370000000 | -7.84 |
| depreciation and amortization | 650000000 | 738000000 | -11.92 |
| deferred income tax | -152000000 | -97000000 | -56.70 |
| stock based compensation | 0 | 0 | NaN |
| accounts receivables | -2728000000 | -5253000000 | 48.07 |
| accounts payables | -8624000000 | 4236000000 | -303.59 |
| inventory | 105000000 | -543000000 | 119.34 |
| acquisitions net | -132000000 | 0 | NaN |
| investments in property plant and equipment | -399000000 | -370000000 | -7.84 |
| net cash used for investing activites | -776000000 | -640000000 | -21.25 |
| debt repayment | 833000000 | -893000000 | 193.28 |
| common stock issued | 62000000 | 40000000 | 55.00 |
| common stock repurchased | 0 | -990000000 | 100.00 |
| dividends paid | -390000000 | -392000000 | 0.51 |
| net cash used provided by financing activities | 439000000 | -2309000000 | 119.01 |
| net change in cash | -279000000 | -1651000000 | 83.10 |
| cash at end of period | 6509000000 | 6788000000 | -4.11 |
| cash at beginning of period | 6788000000 | 8439000000 | -19.56 |
Net Change in Cash: Net Change in Cash increased to -279 million in 2024Q3 from -1,651 million in 2024Q2 representing a change of 83.1%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -399 million in 2024Q3 from -370 million in 2024Q2 representing a change of -7.84%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Dividends Paid: Dividends Paid increased to -390 million in 2024Q3 from -392 million in 2024Q2 representing a change of 0.51%. This indicates a stronger financial position, more confidence in future prospects, and a better commitment to returning value to shareholders.
Operating Cash Flow: Operating Cash Flow decreased to 46 million in 2024Q3 from 265 million in 2024Q2 representing a change of -82.64%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -353 million in 2024Q3 from -105 million in 2024Q2 representing a change of -236.19%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 8,624 million in 2024Q3 from 4,236 million in 2024Q2 representing a change of -303.59%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to -2,728 in 2024Q3 from -5,253 million in 2024Q2 representing a change of 48.07%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 664.15 | 581.6 | 14.19 |
| net income per share | 17.57 | 21.66 | -18.87 |
| operating cash flow per share | 40.2 | 27.96 | 43.74 |
| free cash flow per share | 34.84 | 23.78 | 46.52 |
| cash per share | 29.76 | 22.06 | 34.91 |
| book value per share | 157.71 | 145.22 | 8.61 |
| tangible book value per share | -97.9 | -107.74 | 9.14 |
| shareholders equity per share | 157.28 | 144.96 | 8.50 |
| interest debt per share | 110.16 | 104.41 | 5.51 |
| market cap | 88005959400 | 102564971640.0 | -14.19 |
| enterprise value | 111113959400 | 127733971640.0 | -13.01 |
| pe ratio | 17.04 | 15.3 | 11.39 |
| price to sales ratio | 0.45 | 0.57 | -20.86 |
| pocfratio | 7.45 | 11.85 | -37.13 |
| pfcf ratio | 8.59 | 13.93 | -38.32 |
| pb ratio | 1.9 | 2.29 | -16.70 |
| ptb ratio | 1.9 | 2.29 | -16.70 |
| ev to sales | 0.57 | 0.71 | -19.77 |
| enterprise value over ebitda | 11.61 | 9.9 | 17.28 |
| ev to operating cash flow | 9.41 | 14.76 | -36.26 |
| ev to free cash flow | 10.85 | 17.35 | -37.47 |
| earnings yield | 0.06 | 0.07 | -10.23 |
| free cash flow yield | 0.12 | 0.07 | 62.13 |
| debt to equity | 0.67 | 0.69 | -3.43 |
| debt to assets | 0.2 | 0.22 | -6.27 |
| net debt to ebitda | 2.41 | 1.95 | 23.78 |
| current ratio | 0.77 | 2.67 | -71.32 |
| interest coverage | 5.9 | 6.88 | -14.21 |
| income quality | 2.29 | 1.28 | 78.28 |
| dividend yield | 0.02 | 0.01 | 22.10 |
| payout ratio | 0.28 | 0.21 | 36.01 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.49 | 0.54 | -9.61 |
| capex to operating cash flow | 0.13 | 0.15 | -10.99 |
| capex to revenue | 0.01 | 0.01 | 12.04 |
| capex to depreciation | 0.52 | 0.44 | 17.55 |
| stock based compensation to revenue | 0.0 | 0.0 | -0.08 |
| graham number | 249.36 | 265.78 | -6.18 |
| roic | 0.08 | 0.07 | 24.28 |
| return on tangible assets | 0.07 | 0.1 | -34.89 |
| graham net net | -271.88 | -236.77 | -14.83 |
| working capital | -11365000000 | 18022000000 | -163.06 |
| tangible asset value | -28771000000 | -33352000000 | 13.74 |
| net current asset value | -69059000000 | -70191000000 | 1.61 |
| invested capital | 67822000000 | 100099000000 | -32.25 |
| average receivables | 22820000000 | 18516000000 | 23.24 |
| average payables | 8164000000 | 7215000000 | 13.15 |
| average inventory | 2388500000 | 4249500000 | -43.79 |
| days sales outstanding | 44.28 | 44.52 | -0.55 |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 8.24 | 8.2 | 0.55 |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | 0.11 | 0.15 | -25.22 |
| capex per share | 5.35 | 4.18 | 27.94 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 17.04 on 2023-12-31 from 15.30 on 2022-12-31, representing a change of 11.39%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.67 on 2023-12-31 from 0.69 on 2022-12-31, representing a change of -3.43%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 0.77 on 2023-12-31 from 2.67 on 2022-12-31, representing a change of -71.32%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| CI | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 228.74 | 215.11 | 6.34 |
| net income per share | 2.65 | 5.51 | -51.80 |
| operating cash flow per share | 0.17 | 0.94 | -82.47 |
| free cash flow per share | -1.27 | -0.37 | -239.42 |
| cash per share | 24.25 | 27.94 | -13.23 |
| book value per share | 151.9 | 147.71 | 2.84 |
| tangible book value per share | -114.44 | -117.05 | 2.23 |
| shareholders equity per share | 151.17 | 147.02 | 2.82 |
| interest debt per share | 119.15 | 114.77 | 3.81 |
| market cap | 96468643080 | 91725263910 | 5.17 |
| enterprise value | 123382643080 | 116829263910 | 5.61 |
| pe ratio | 32.63 | 14.81 | 120.30 |
| price to sales ratio | 1.51 | 1.52 | -0.14 |
| pocfratio | 2097.14 | 346.13 | 505.88 |
| pfcf ratio | -273.28 | -873.57 | 68.72 |
| pb ratio | 2.29 | 2.22 | 3.26 |
| ptb ratio | 2.29 | 2.22 | 3.26 |
| ev to sales | 1.94 | 1.93 | 0.27 |
| enterprise value over ebitda | 55.63 | 37.85 | 46.99 |
| ev to operating cash flow | 2682.23 | 440.87 | 508.40 |
| ev to free cash flow | -349.53 | -1112.66 | 68.59 |
| earnings yield | 0.01 | 0.02 | -54.61 |
| free cash flow yield | -0.0 | -0.0 | -219.66 |
| debt to equity | 0.78 | 0.77 | 0.99 |
| debt to assets | 0.21 | 0.21 | -1.58 |
| net debt to ebitda | 12.13 | 8.13 | 49.21 |
| current ratio | 0.86 | 0.83 | 3.36 |
| interest coverage | 4.61 | 6.43 | -28.38 |
| income quality | 0.06 | 0.17 | -67.43 |
| dividend yield | 0.0 | 0.0 | -5.40 |
| payout ratio | 0.53 | 0.25 | 108.40 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.47 | 0.49 | -4.65 |
| capex to operating cash flow | 8.67 | 1.4 | 521.24 |
| capex to revenue | 0.01 | 0.01 | 2.39 |
| capex to depreciation | 0.61 | 0.5 | 22.44 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 95.01 | 134.96 | -29.60 |
| roic | 0.01 | 0.02 | -42.82 |
| return on tangible assets | 0.01 | 0.02 | -56.30 |
| graham net net | -305.84 | -351.72 | 13.05 |
| working capital | -7838000000 | -9158000000 | 14.41 |
| tangible asset value | -31867000000 | -32907000000 | 3.16 |
| net current asset value | -66119000000 | -63109000000 | -4.77 |
| invested capital | 69921000000 | 68827000000 | 1.59 |
| average receivables | 13923000000 | 0 | NaN |
| average payables | 8895000000 | 8696500000 | 2.28 |
| average inventory | 5128000000 | 4901500000 | 4.62 |
| days sales outstanding | 39.35 | 0 | NaN |
| days payables outstanding | 80.44 | 0 | NaN |
| days of inventory on hand | 48.02 | 0 | NaN |
| receivables turnover | 2.29 | 0 | NaN |
| payables turnover | 1.12 | 0 | NaN |
| inventory turnover | 1.87 | 0 | NaN |
| roe | 0.02 | 0.04 | -53.13 |
| capex per share | 1.43 | 1.32 | 8.87 |
ROE: Return on Equity (ROE) decreased to 0.02 on 2024-09-30 Q3 from 0.04 on 2024-06-30 Q2, representing a change of -53.13%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 0.86 on 2024-09-30 Q3 from 0.83 on 2024-06-30 Q2, representing a change of 3.36%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. However, it's below 1, indicating potential liquidity issues.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 32.63 on 2024-09-30 Q3 from 14.81 on 2024-06-30 Q2, representing a change of 120.30%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.78 on 2024-09-30 Q3 from 0.77 on 2024-06-30 Q2, representing a change of 0.99%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-16 10:50:00
Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth.
Sentiment: Neutral
Publish Date: 2025-01-15 11:31:15
The report comes at a time when insurers are grappling with rising medical costs.
Sentiment: Neutral
Publish Date: 2025-01-14 09:00:00
BLOOMFIELD, Conn. , Jan. 14, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2024 financial results on Thursday, January 30, 2025, and will host a conference call the same day.
Sentiment: Positive
Publish Date: 2025-01-13 08:00:00
BLOOMFIELD, Conn. , Jan. 13, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasdaq: PGNY) that makes best-in-class fertility and family-building services accessible and equitable for more employers.
Sentiment: Positive
Publish Date: 2025-01-12 14:45:04
As the calendar turns to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.
Sentiment: Positive
Publish Date: 2025-01-12 07:30:00
The U.S. economy added 256,000 jobs last month, far exceeding expectations, which suggests a strong economy but reduces the likelihood of further Fed rate cuts. Rising long-term rates increase borrowing costs and competition for stocks, negatively impacting rate-sensitive sectors like utilities, real estate, and consumer staples. Despite a challenging market environment, equities still offer value, particularly in high-quality blue-chip stocks.
Sentiment: Neutral
Publish Date: 2025-01-10 11:08:36
Employers are increasingly requiring workers on GLP-1 medications to enroll in nutrition and lifestyle coaching programs. Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.
Sentiment: Positive
Publish Date: 2025-01-08 06:00:00
BLOOMFIELD, Conn. , Jan. 8, 2025 /PRNewswire/ -- The Cigna Group Foundation announced today 22 recipients for the first year of its new grant program that aims to improve veteran mental health with a focus on housing stability.
Sentiment: Positive
Publish Date: 2025-01-07 14:00:44
Despite market challenges, CI's strong fundamentals and growth drivers make it worth holding for long-term investors looking to capitalize on future recovery opportunities.
Sentiment: Positive
Publish Date: 2025-01-07 09:23:10
Dividend stocks are usually thought of as a way to provide stable, passive returns. However, the magnitude of their importance is often overlooked.
Sentiment: Positive
Publish Date: 2025-01-06 09:49:21
The health insurance industry has received a lot of backlash over its managed care practices that bog down providers with pre-authorizations and rampant medical claim denials. The rise in medical benefits ratios (MBRs) driven by Medicare Advantage plans have squeezed margins for major health insurance providers like Humana Inc. NYSE: HUM, UnitedHealth Group Inc. NYSE: UNH, and CVS Health Co. NYSE: CVS.
Sentiment: Positive
Publish Date: 2025-01-04 08:00:00
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (January 2025)
Sentiment: Positive
Publish Date: 2024-12-31 10:40:38
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sentiment: Negative
Publish Date: 2024-12-23 09:38:26
Wendell Potter, Center for Health and Democracy president and former Cigna vice president, joins 'Squawk Box' to discuss public anger at the health care industry, problems with health insurance, and more.
Sentiment: Positive
Publish Date: 2024-12-19 13:57:30
Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sentiment: Positive
Publish Date: 2024-12-18 08:30:00
The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability.
Sentiment: Positive
Publish Date: 2024-12-17 13:40:11
Barclays analyst Andrew Mok said that while the existential risk to pharmacy benefit managers is low, President-elect Trump's comments yesterday point to additional headline risk and greater support for legislation. Trump said he planned to "knock out the middleman" which is the latest in a string of negative headlines that drove PBM-owned stocks Cigna (CI), CVS Health (CVS) and UnitedHealth (UNH) lower, the analyst told investors yesterday in a research note. The firm believes PBMs "are the only market-based check on drug pricing that exists today," and eliminating the "middleman" would effectively put the government in charge of negotiating drug prices for both private and government-sponsored health plans. Trump, said, "The horrible middleman that makes more money frankly than the drug companies and they don't do anything except they're a middleman, we're going to knock out the middleman." Barclays fact-checked this and notes the average EBIT margins of the top six U.S. pharmaceutical companies is 37%, nearly 8-10 times PBM margins, which are closer to 3%-5%. Four of the six largest drug manufacturers, Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Pfizer (PFE) are estimated to earn more operating profits this year than the "Big Three" PBMs combined, according to Barclays. CVS Health -2.11 (-4.53%) Cigna -8.06 (-2.95%) UnitedHealth -19.06 (-3.83%) Johnson & Johnson +1.65 (+1.15%) AbbVie +2.88 (+1.68%) Merck +0.07 (+0.07%) Pfizer +1.115 (+4.41%)
Sentiment: Negative
Publish Date: 2024-12-17 12:21:01
Shares in major healthcare companies fell yesterday after president-elect Donald Trump made comments that he wanted to “knock out” prescription drug industry middlemen. The fall makes this yet another week since the killing of UnitedHealth CEO Brian Thompson that the business practices of companies that operate America's private healthcare system have come under increased scrutiny.
Sentiment: Positive
Publish Date: 2024-12-15 07:00:00
Cigna's strong fundamentals, including consistent revenue and EPS growth, a solid balance sheet, and undervalued stock price, support a buy rating. The company's Q3 results showed a 29.9% revenue increase and a 10.9% rise in non-GAAP EPS, driven by customer growth and price hikes. Cigna's dividend yield and growth potential are robust, with a low payout ratio and projected double-digit annual EPS growth supporting future dividend increases.
Sentiment: Negative
Publish Date: 2024-12-13 15:46:05
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
